Zenocutuzumab

LEXINGTON, Mass., July 2, 2026 Partner Therapeutics (PTx) has announced the publication of pivotal results from the Phase 2...

LEXINGTON, Mass., May 11, 2026 Partner Therapeutics, Inc. (PTx) announced that the U.S. Food and Drug Administration (FDA) has...

LEXINGTON, Massachusetts, United States – May 6, 2026 Partner Therapeutics has announced that the U.S. Food and Drug Administration...

LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...

LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...